# Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

> **NCT06134362** · PHASE3 · RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 3508 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CAB LA

## Key facts

- **NCT ID:** NCT06134362
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-14
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 3508 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06134362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06134362, "Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06134362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*